The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
Updated results from the EMBER-3 study showed that the drug -- Inluriyo (imlunestrant) -- as a standalone treatment cut the risk of progression or death by 38%
Retatrutide, tested at 9 mg and 12 mg doses alongside diet and exercise, met all primary and key secondary endpoints
The Healey ALS Platform Trial is a multicenter, double-blind, placebo-controlled
The cobas Mass Spec solution Ionify reagent portfolio now covers therapeutic drug monitoring for immunosuppressants and antibiotics
The companies aim to expand treatment options for millions living with metabolic disorders
This is the first approval of a prescription transdermal dosage Form in the European markets from this facility
Dr. Reddy's commits to achieving Net Zero greenhouse gas emissions across its value chain by FY 2045
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
Subscribe To Our Newsletter & Stay Updated
